The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer | Zendy

Xuelu Li | Zendy; Chen Song | Zendy; Gena Huang | Zendy; Siwen Sun | Zendy; Jingjing Qiao | Zendy; Jinbo Zhao | Zendy; Zuowei Zhao | Zendy; Man Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer

Author(s) -

Xuelu Li,

Chen Song,

Gena Huang,

Siwen Sun,

Jingjing Qiao,

Jinbo Zhao,

Zuowei Zhao,

Man Li

Publication year - 2017

Publication title -

oncotargets and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.054

H-Index - 60

ISSN - 1178-6930

DOI - 10.2147/ott.s132806

Subject(s) - breast cancer , medicine , immunohistochemistry , oncology , hazard ratio , cancer , survival analysis , proportional hazards model , overall survival , phenotype , cancer research , pathology , biology , gene , confidence interval , biochemistry

HER2 overexpression is associated with aggressive phenotypes in breast cancer, including increased tumor proliferation, greater invasiveness, and reduced overall survival. The overall response rate to HER2-targeted therapies remains <30%. There is an urgent need for the identification of efficient markers to predict patients with a poor prognosis. This study was designed to investigate the correlation between EphB4 and EphrinB2 expression and the clinicopathological characteristics of HER2-positive breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research